PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-89.95%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-95.43%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-134.36%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-134.21%
Negative EPS growth while GNPX is at 34.62%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-134.21%
Negative diluted EPS growth while GNPX is at 34.62%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-141.82%
Negative OCF growth while GNPX is at 7.14%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-141.82%
Negative FCF growth while GNPX is at 7.14%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.42%
Negative 10Y OCF/share CAGR while GNPX stands at 91.62%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-31.42%
Negative 5Y OCF/share CAGR while GNPX is at 96.48%. Joel Greenblatt would question the firm’s operational model or cost structure.
-183.28%
Negative 3Y OCF/share CAGR while GNPX stands at 96.26%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
1.36%
Below 50% of GNPX's 99.56%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
1.36%
Below 50% of GNPX's 96.58%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-52.35%
Negative 3Y CAGR while GNPX is 96.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-201.38%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-99.57%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-12.67%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-28.84%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
60.35%
SG&A growth well above GNPX's 52.68%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.